<?xml version="1.0" encoding="UTF-8"?><feed xmlns="http://www.w3.org/2005/Atom">
  <title>识林 | wechat-feeds</title>
  <id>https://github.com/hellodword/wechat-feeds</id>
  <updated>2020-11-29T16:39:06+08:00</updated>
  <subtitle>服务于制药行业企业、机构及人员的知识与管理平台</subtitle>
  <link href="https://github.com/hellodword/wechat-feeds"></link>
  <author>
    <name>hellodword</name>
  </author>
  <entry>
    <title>【周末杂谈】受益与贡献</title>
    <updated>2020-11-29T06:19:37+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-11-29:/s/Jv9quihn6LsxGBpgU2zPWg</id>
    <link href="https://mp.weixin.qq.com/s/Jv9quihn6LsxGBpgU2zPWg" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>FDA 2020 财年药品检查观察项和趋势</title>
    <updated>2020-11-28T06:38:21+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-11-28:/s/MkinQNYfk7DB4tKsqExtKw</id>
    <link href="https://mp.weixin.qq.com/s/MkinQNYfk7DB4tKsqExtKw" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>欧盟发布药物战略强调仿制药竞争和强制许可等问题</title>
    <updated>2020-11-27T05:29:25+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-11-27:/s/EayiDHO1d6WPFGWDBdCx3g</id>
    <link href="https://mp.weixin.qq.com/s/EayiDHO1d6WPFGWDBdCx3g" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>FDA 解释瑞德西韦批准依据，暗驳 WHO 的否定建议</title>
    <updated>2020-11-27T05:29:25+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-11-27:/s/PR9czbGF-_M7BVU0OKDmDw</id>
    <link href="https://mp.weixin.qq.com/s/PR9czbGF-_M7BVU0OKDmDw" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>FDA 远程记录审查缺乏沟通互动引发业界担忧</title>
    <updated>2020-11-26T06:00:08+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-11-26:/s/qmGeOrPpyiNg1zboj9UuIQ</id>
    <link href="https://mp.weixin.qq.com/s/qmGeOrPpyiNg1zboj9UuIQ" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>FDA 发布复杂仿制药开发和申报正式会议定稿指南</title>
    <updated>2020-11-26T06:00:08+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-11-26:/s/qmcwSMnUy5W2G_PW4VS9fA</id>
    <link href="https://mp.weixin.qq.com/s/qmcwSMnUy5W2G_PW4VS9fA" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>美国仿制药协会敦促 FDA 重新审视亚硝胺问题</title>
    <updated>2020-11-25T06:43:14+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-11-25:/s/tlEzmzSxxm4PqOuRy8KpTg</id>
    <link href="https://mp.weixin.qq.com/s/tlEzmzSxxm4PqOuRy8KpTg" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>制药商提请 FDA 延长亚硝胺风险评估期限</title>
    <updated>2020-11-25T06:43:14+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-11-25:/s/UigdVA5fjuLNwQRTNnAniA</id>
    <link href="https://mp.weixin.qq.com/s/UigdVA5fjuLNwQRTNnAniA" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>阿斯利康新冠疫苗初步分析平均 70% 效力，对供应链要求相对更简单</title>
    <updated>2020-11-24T06:19:21+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-11-24:/s/vVGI2YkL9wePcinh0wRsxg</id>
    <link href="https://mp.weixin.qq.com/s/vVGI2YkL9wePcinh0wRsxg" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>IPEM 2021年开始招生！</title>
    <updated>2020-11-24T06:19:21+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-11-24:/s/aV0Dn_p1jhXruXWRv9O1bQ</id>
    <link href="https://mp.weixin.qq.com/s/aV0Dn_p1jhXruXWRv9O1bQ" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>一周回顾：附条件批准上市技术指导原则，FDA发布新一批BE指南，新发布两项新冠治疗药紧急使用授权，欧美各自宣布新冠专家会计划</title>
    <updated>2020-11-23T06:35:47+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-11-23:/s/CvuLBlEbYVCOy8mN0RpqqQ</id>
    <link href="https://mp.weixin.qq.com/s/CvuLBlEbYVCOy8mN0RpqqQ" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>欧盟发布新冠疫苗批准考量，欧美将相继于下月直播疫苗专家会</title>
    <updated>2020-11-23T06:35:47+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-11-23:/s/RKFuGi57xX4sNcmYTMtsgg</id>
    <link href="https://mp.weixin.qq.com/s/RKFuGi57xX4sNcmYTMtsgg" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>【周末杂谈】这也算透明？</title>
    <updated>2020-11-22T06:34:22+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-11-22:/s/wOlc2QYyNpJy--lQB3R5lQ</id>
    <link href="https://mp.weixin.qq.com/s/wOlc2QYyNpJy--lQB3R5lQ" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>瑞德西韦：WHO不建议用于新冠治疗，FDA授权与抗炎药联用</title>
    <updated>2020-11-21T06:20:33+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-11-21:/s/TFdNnNFsNDqCyFpGeawvUw</id>
    <link href="https://mp.weixin.qq.com/s/TFdNnNFsNDqCyFpGeawvUw" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>FDA 生物类似与可互换产品问答指南增加关于可互换性的四个问答</title>
    <updated>2020-11-20T06:35:27+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-11-20:/s/lLb9QEKrXSRZEfNUdob7OA</id>
    <link href="https://mp.weixin.qq.com/s/lLb9QEKrXSRZEfNUdob7OA" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>仿制药标签修订和孤儿药专营权成本回收法案美国众议院获通过</title>
    <updated>2020-11-20T06:35:27+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-11-20:/s/aJL_y_O-LUFYnKJxfpzuSQ</id>
    <link href="https://mp.weixin.qq.com/s/aJL_y_O-LUFYnKJxfpzuSQ" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
</feed>